|
Market Cap (24-Jun) $80,439,416 (1,515th) |
Close (30-Jun) $0.005 |
Volume (30-Jun) 402,075 |
Shortsold (10-Feb) 29,568 (0.00%) (623rd) |
|
52w High $0.027 |
52w Low $0.003 |
P/E 4.78 |
EPS 0 |
AVE released this announcement to the ASX on 22 February 2023, 8:25. The announcement is marked as price sensitive, and is 2 page(s) in length and 78.69kb in size.
You can view all announcements from AVE and see how they appear on a price chart on the announcements page.
At the date of this announcement, AVE was 0.001% short sold according to ASIC data. It was ranked the 623rd most shorted stock on the ASX. It remains ranked 623rd as of the latest reported data (10 February 2025).
| Other Recent Announcements from AVE | |
|---|---|
| Update - Application for quotation of securities - AVE | 28 June 2023, 11:48 |
| Application for quotation of securities - AVE | 28 June 2023, 11:43 |
| AVE CBD capsule passes two-year stability milestone | 22 June 2023, 8:57 |
| Clinical CBD program expands with the Lambert Initiative | 22 February 2023, 8:25 |
| December 2022 Quarterly Activities Report & Appendix 4C | 31 January 2023, 8:36 |
| Athenex submits Avecho's phytonadione to FDA pre-IND | 12 January 2023, 11:49 |
| Avecho receives ethics approval for Phase III CBD trial | 22 December 2022, 9:52 |
You must be logged in to post a reply.
Avecho Biotechnology 